A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy
Status:
Active, not recruiting
Trial end date:
2022-04-26
Target enrollment:
Participant gender:
Summary
The main aims of the study are:
- To check for side effects from TAK-994 and check what dose of TAK-994 participants can
tolerate.
- To check what dose range provides adequate relief of narcolepsy symptoms.
- To check how much TAK-994 stays in the blood of participants, over time.
The study will have 4 parts. Participants can only join 1 of the parts.
A. Participants with type 1 narcolepsy will take either TAK-994 or placebo tablets for 28
days. A placebo looks just like TAK-994 but will not have any medicine in it.
B. Participants with type 1 narcolepsy will take 1 of 3 doses of TAK-994 or placebo tablets
for 56 days.
C. Participants with type 1 narcolepsy in China only will take TAK-994 or placebo tablets for
56 days.
D. Participants with type 2 narcolepsy will take either TAK-994 or placebo tablets for 28
days.